Thursday, November 19, 2026

More U.S. women are opting for menopause hormone therapy, according to fresh prescription data. Monthly dispensing for women aged 40‑74 jumped from roughly two million prescriptions in 2023 to about 4.9 million by 2026, researchers reported November 19 in JAMA. The sharp increase began in 2024 and accelerated through 2025 and into 2026, even before and after the FDA removed the black‑box warning from product labeling in November.

The analysis, which used aggregated pharmacy dispensing records, also showed a rise in prescribing intensity: the rate grew from about 28 prescriptions per 1,000 women to roughly 67 per 1,000 during the study period.

While the study does not explain the drivers, experts cite heightened awareness of women’s health, updated clinical guidance that favors individualized therapy, and the influence of social media. The Menopause Society now recommends hormone therapy for symptomatic women under age 60 or within ten years of menopause onset, barring certain risk factors.

“Greater attention to women’s health, updated medical guidance supporting individualized menopause hormone therapy and social media may all be contributing to increased interest,” says Dana Sarnak of Johns Hopkins School of Medicine. Clinicians are reporting more patients seeking care.

The swing follows a period of caution that began in the early 2000s after the Women’s Health Initiative raised safety alarms, later judged overstated. Subsequent research has refined the risk‑benefit profile across age groups.

Today’s formulations include safer options such as transdermal patches and vaginal gels, which the study found saw increased use. Oral estrogen prescriptions remained steady, while progesterone products also rose. A shortage of estrogen patches this year reflects the surge in demand, according to the FDA.

Source link

Exit mobile version